Immunovia, Inc. Receives Approval to Begin Testing Patients for Pancreatic Cancer with the IMMray™ PanCan-d Test
LUND, SWEDEN – Immunovia AB (publ) (“Immunovia”), a diagnostic company that develops highly accurate blood tests for the early detection of cancer and autoimmune diseases, today announced that Immunovia, Inc. has received final approval to begin patient testing for the IMMray PanCan-d test - the first blood test on the market dedicated to the early detection of pancreatic cancer. This approval was received from the Massachusetts Department of Public Health on August 3, 2021. Immunovia, Inc. received its CLIA Certificate of Registration on June 21, 2021 (CLIA Number: 22D2227265). As a result,